Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primer

Area of Science:

• Cardiovascular Medicine
• Hematology
• Genetics

Background:

• Atherosclerotic cardiovascular disease (ASCVD) poses a significant risk despite current preventive strategies.
• Clonal hematopoiesis, driven by somatic mutations, is increasingly recognized as a common and potent independent risk factor for ASCVD.
• Mutations in TET2 and JAK2 are prevalent in clonal hematopoiesis and linked to cardiovascular conditions.

Purpose of the Study:

• To review the emerging role of clonal hematopoiesis as a cardiovascular risk factor.
• To summarize current understanding of the mechanisms linking clonal hematopoiesis to ASCVD.
• To highlight the significance of TET2 and JAK2 mutations in this context.

Main Methods:

• Review of experimental studies, primarily in mouse models.
• Analysis of existing literature on clonal hematopoiesis and cardiovascular disease.
• Synthesis of data linking specific gene mutations to atherosclerosis development.

Main Results:

• Experimental evidence suggests TET2 and JAK2 mutations promote inflammation.
• These mutations are causally linked to accelerated atherosclerosis in preclinical models.
• Clonal hematopoiesis emerges as a significant contributor to cardiovascular risk.

Conclusions:

• Clonal hematopoiesis represents an important, emerging cardiovascular risk factor.
• Understanding the mechanisms, such as inflammation and accelerated atherosclerosis, is crucial.
• This knowledge may inform future primary and secondary prevention strategies for ASCVD.